Imatinib Tarbis (Imatinib)

Imatinib blocks the activity of specific tyrosine kinases, chiefly BCR‑ABL, c‑KIT, and PDGFR. By binding to the ATP‑binding site of these enzymes, it prevents downstream signaling that promotes uncontrolled cell growth, thereby inducing apoptosis of malignant cells that rely on these pathways.

The dose of Imatinib Tarbis is individualized by the prescribing physician based on the specific indication, disease stage, patient weight, renal and hepatic function, and other clinical factors. Only a qualified healthcare professional should determine the appropriate regimen.

Safety data for Imatinib in pregnancy and lactation are limited. It is classified as contraindicated or to be used only if the potential benefit justifies the risk. Women who are pregnant, planning pregnancy, or breastfeeding should discuss alternatives with their oncologist.

To place an order, submit an enquiry on the product page at gnhindia.com specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Imatinib was the first BCR‑ABL inhibitor and remains a standard of care for CML and GIST. Newer agents such as dasatinib or nilotinib may offer activity against certain resistant mutations, but Imatinib’s long‑term safety profile and extensive clinical experience make it a widely used first‑line option.

Imatinib Tarbis should be stored at room temperature, below 25 °C, in its original packaging. Protect the product from moisture and direct sunlight to maintain its stability throughout its shelf life.

Imatinib Tarbis is taken orally, usually with a glass of water. It can be swallowed with or without food, but patients should follow the specific instructions provided by their healthcare provider to ensure consistent absorption.

Serious risks include severe neutropenia, hepatotoxicity, and cardiac failure. Patients should be monitored regularly for blood‑cell counts, liver function tests, and signs of heart dysfunction. Prompt reporting of any concerning symptoms to a physician is essential.

Patients with known hypersensitivity to imatinib or any of its excipients should avoid the product. Caution is also advised for individuals with severe hepatic impairment, uncontrolled cardiac disease, or those taking contraindicated interacting medications.